Momordica charantia for type 2 diabetes mellitus
Ooi CP, Yassin Z, Hamid TA
Published in Cochrane Database of Systematic Reviews
Abstract
Cochrane systematic review of randomized controlled trials of Momordica charantia for type 2 diabetes mellitus.
Key Findings
There is insufficient evidence to recommend Momordica charantia for type 2 diabetes; trials showed no statistically significant difference in glycaemic control versus placebo or metformin.
Conclusions
Bitter melon cannot currently be recommended for diabetes management.
Limitations
Few trials, small samples, high risk of bias, short duration.
Supplements Studied
There is insufficient evidence to recommend Momordica charantia for type 2 diabetes; trials showed no statistically significant difference in glycaemic control versus placebo or metformin.
Outcomes Measured
There is insufficient evidence to recommend Momordica charantia for type 2 diabetes; trials showed no statistically significant difference in glycaemic control versus placebo or metformin.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.